Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00444925 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,712
- Enrollment target
NCT00444925: Completed Phase 3 study, sponsored by Pfizer.
NCT00444925 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,712 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (122% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00444925, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,712 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
Primary Outcome
UUI per 24 hours: total number of micturitions with Urinary Sensation Scale (USS) of 5 divided by total number of diary days collected at visit. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Change: mean at observation minus mean at baseline.
Interventions
- DRUG placebo
- DRUG fesoterodine fumarate
- DRUG tolterodine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,712 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
What the finished NCT00444925 record still lists
NCT00444925 is an interventional study that assigns participants to a tested intervention. Its 1,712 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (122% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00444925 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00444925 about?
NCT00444925 is a clinical study titled "Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)". To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
What is the current status of trial NCT00444925?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,712 participants. The study started on 2007-04. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00444925?
The interventions under investigation include: placebo (DRUG), fesoterodine fumarate (DRUG), tolterodine tartrate (DRUG).
Who is sponsoring clinical trial NCT00444925?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00444925's enrollment target sits among peer trials
1,712 132nd of 2000 higher than 1,869 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia